Streamlining Rheumatology Naviguard Prior Authorizations

Klivira empowers rheumatology practices to efficiently navigate the complexities of prior authorizations, particularly for high-cost biologics and specialty drugs under UnitedHealthcare's Naviguard utilization management.

Prior authorization for rheumatology treatments, especially biologics and JAK inhibitors, represents a significant administrative burden. When coupled with the specific requirements of Naviguard, a UnitedHealthcare utilization management solution, practices face increased complexity. Klivira provides a robust platform designed to automate and optimize these critical workflows, ensuring timely patient access to necessary therapies.

The Challenge of Rheumatology Naviguard Prior Authorizations

Rheumatology practices frequently encounter prior authorization requirements for chronic disease management, particularly with advanced agents. Naviguard, as a key component of UnitedHealthcare's utilization management, often mandates specific step therapy protocols, documentation, and re-authorization schedules for these high-cost therapies. This intersection creates a high-volume, high-stakes environment for PA coordinators.

Key Prior Authorization Triggers in Rheumatology

Biologics for autoimmune conditions (e.g., Humira, Enbrel, Stelara, Skyrizi, Rinvoq)
JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib)
Infusion therapy for conditions like rheumatoid arthritis or lupus
Advanced imaging (e.g., MRI for inflammatory arthritis assessment)
DEXA scans for osteoporosis management in chronic steroid patients

Navigating UnitedHealthcare's Utilization Management with Klivira

Naviguard, part of the UnitedHealth Group, plays a pivotal role in utilization management for UnitedHealthcare members. Klivira integrates directly with payer channels, including electronic prior authorization (ePA) portals and X12 278 transactions, to streamline the submission process for rheumatology Naviguard requests. Our platform interprets payer-specific policy logic, including those informed by ACR Treatment Guidelines, to guide accurate submissions.

Critical Documentation for Rheumatology Biologic PAs

Diagnosis documentation (ICD-10 with disease-specific criteria like 2010 ACR/EULAR for RA)
Disease activity assessment (e.g., DAS28, CDAI, PASI, BASDAI, SLEDAI)
Prior conventional DMARD trial and response (or contraindication)
Step therapy compliance, including biosimilar substitution requirements
Screening completion (e.g., TB, hepatitis B/C, immunization status)

Klivira's Intelligent Automation for Rheumatology Naviguard Workflows

Klivira's platform is engineered to address the unique demands of rheumatology Naviguard prior authorizations. We leverage ACR-guideline-aware policy logic to ensure step therapy sequencing is correctly applied per indication. Our system manages biosimilar substitution routing, handling per-payer mandates and brand-to-biosimilar conversion workflows. This comprehensive approach minimizes manual effort and reduces the likelihood of denials.

Common Naviguard Denial Reasons in Rheumatology

Step therapy not completed or documented in the required sequence
Biosimilar substitution required before brand biologic approval
Disease activity not adequately documented (missing DAS28, CDAI, etc.)
Conservative-care duration insufficient per payer-required duration
Screening documentation gaps (TB, hepatitis, or immunization incomplete)
Off-indication use without supporting payer-specific policy

Frequently asked questions

How does Klivira handle Naviguard's step therapy requirements for rheumatology biologics?

Klivira's platform incorporates ACR-guideline-aware policy logic and payer-specific rules to accurately sequence step therapy. This includes managing biosimilar substitution mandates and ensuring the correct trial of conventional DMARDs or TNF inhibitors before advancing to other biologics or JAK inhibitors.

What are common documentation pitfalls for rheumatology PAs with Naviguard?

Frequent issues include incomplete documentation of disease activity scores (e.g., DAS28), failure to clearly record prior conventional DMARD trials, and missing evidence of required screenings like TB or hepatitis. Klivira helps flag these gaps proactively to prevent denials.

Does Klivira support re-authorization workflows for chronic rheumatology treatments managed by Naviguard?

Yes, Klivira automates the periodic re-authorization process typical for chronic rheumatology biologics. The system prompts for continuous documentation of disease response and adherence to ongoing treatment criteria, ensuring timely re-submissions and continuity of care.

How does Klivira address the medical vs. pharmacy benefit split for biologics in rheumatology?

Klivira's platform intelligently routes prior authorization requests based on the administration mode (self-administered injections vs. provider-administered infusions) and the specific payer's policy. This ensures the correct benefit channel is addressed, whether it's medical or pharmacy, for the same agent.

Can Klivira integrate with our EMR for Naviguard rheumatology PAs?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR and other APIs. This connectivity streamlines data exchange, allowing for efficient extraction of necessary clinical documentation directly from the EMR to populate Naviguard prior authorization requests.